NWI Management LP Makes New $15.87 Million Investment in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

NWI Management LP acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 720,000 shares of the company's stock, valued at approximately $15,869,000. Teva Pharmaceutical Industries comprises approximately 0.7% of NWI Management LP's investment portfolio, making the stock its 20th largest position. NWI Management LP owned about 0.06% of Teva Pharmaceutical Industries at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Oarsman Capital Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $44,000. Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $66,000. IFP Advisors Inc lifted its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TEVA. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research note on Thursday, January 30th. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $24.43.

Teva Pharmaceutical Industries Stock Down 0.1%

TEVA traded down $0.01 during trading hours on Monday, reaching $16.93. 2,566,134 shares of the stock traded hands, compared to its average volume of 9,975,797. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a market cap of $19.20 billion, a price-to-earnings ratio of -11.68, a PEG ratio of 1.44 and a beta of 0.62. The firm's fifty day simple moving average is $15.35 and its two-hundred day simple moving average is $17.41.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the prior year, the firm posted $0.48 EPS. The firm's revenue was up 1.9% compared to the same quarter last year. As a group, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.